Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.
about
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infectionDepletion of latent HIV-1 infection in vivo: a proof-of-concept studyEpisomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failureDeep molecular characterization of HIV-1 dynamics under suppressive HAARTReappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infectionResidual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolutionAdvances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring.Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy.In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA.A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.Immunologic pressure within class I-restricted cognate human immunodeficiency virus epitopes during highly active antiretroviral therapyLow human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.Antiretroviral resistance during successful therapy of HIV type 1 infection.Rapid turnover of 2-LTR HIV-1 DNA during early stage of highly active antiretroviral therapy.Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsShort communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection.Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs.Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistenceA randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.Latency in human immunodeficiency virus type 1 infection: no easy answers.The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAARTHIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.Treatment-induced decline of human immunodeficiency virus-1 p24 and HIV-1 RNA in lymphoid tissue of patients with early human immunodeficiency virus-1 infectionImpact of seminal cytomegalovirus replication on HIV-1 dynamics between blood and semenAn increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cellsLong-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantationEnvelope gene evolution and HIV-1 neuropathogenesis.
P2860
Q24550678-605AF95A-D150-43EC-8FC6-84404A6DBD96Q28111910-D1B58456-FA9E-4A2C-A057-7E053A24BDC6Q28477257-6D4D50B4-6935-4D0D-88FB-4522A8DD6F40Q28477677-022AAAF9-B1D5-4212-A51F-9DF657E996F6Q28478934-45891E57-C912-4424-8D29-16BDE4116359Q28539563-A6D0A69A-5399-49F2-814B-C9B3AEECBDCDQ30249830-9E60A64C-C3E1-4828-A160-7727ED146D1CQ33510903-9FD2D20A-C789-4624-A631-0ABC67FDBB84Q33705883-78A02DC5-49B4-43E2-8410-ADCB3A340156Q33716348-2E287588-5AC9-41F7-AFE7-488CD61E6D97Q33724206-FCDD8274-D6E9-4194-8723-D2A069887847Q33724247-F40942E2-4290-421F-9343-8F21BEA276FCQ33737646-73533379-7CA9-44D2-8A2E-3199F86C718BQ33883813-C63FEB49-298A-41A1-A722-2438EE393870Q33892114-E3BD8E7B-4523-4B4E-B6D3-6EB9B0EB55D1Q33908838-D8A910C5-2458-4003-A29F-2AF17CC2516FQ33919308-88EAAC61-E04C-4167-B421-C6A3056543ABQ33936651-64937348-6057-4F8B-8CD7-B8127FE0B17AQ34028490-543E37F7-60D4-439B-B08E-DEA5EA474B01Q34057868-A6CB3C13-D7B9-41AA-8F50-59C8ED445889Q34085094-67CEDA7C-1FD3-4985-9017-8CE422BECD10Q34289476-9C4C38F8-7A51-49B3-84B2-73CA7A9CAF3EQ34326482-F3803454-E267-4EEB-A833-83B686D1E2D6Q34328792-11015EAC-011E-4D0D-9DDB-61529FBB3C2EQ34333195-5FDAFF9A-06C0-46F8-9062-5E8D228D96A3Q34345655-A476D69B-7304-405C-AB44-62489D13D425Q34648499-51443E53-BC3D-4A8C-B920-2112C7137115Q34869426-9C39682F-BDF0-4C9B-9E7A-C6DC2B61FE3AQ34960856-F8156DF0-65CB-4726-8C0E-6B33DBCD1C33Q35024683-A1CE19EF-A0D7-4D1C-BE4F-1AB0E32D67C4Q35044157-D03A00AC-0605-484E-A5A2-BFB3B58E39B7Q35076758-14425A05-B341-44F6-B35C-5DE444C63626Q35088292-FF44CAC9-9D05-4E6D-8F65-E567F481E639Q35557244-69960146-B16B-4D91-AC0E-2BB436F41FBDQ35729054-5BFB97A1-845E-420E-803C-F41F7DBFC879Q35745547-1E9FFCA0-B44B-49C9-B397-E7F391A84CBBQ36320655-D9FD2BE8-1C2F-4D6F-8001-51B405743977Q36559821-10DA2421-B2C1-4A5A-8E14-E856683C9498Q36796554-D743C214-AC67-4C93-97A1-F30BD33FF194Q36847475-D37A10FB-7BE4-4912-8DCC-871171E390A5
P2860
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Evolution of envelope sequence ...... g of potent antiviral therapy.
@ast
Evolution of envelope sequence ...... g of potent antiviral therapy.
@en
type
label
Evolution of envelope sequence ...... g of potent antiviral therapy.
@ast
Evolution of envelope sequence ...... g of potent antiviral therapy.
@en
prefLabel
Evolution of envelope sequence ...... g of potent antiviral therapy.
@ast
Evolution of envelope sequence ...... g of potent antiviral therapy.
@en
P2093
P2860
P1433
P1476
Evolution of envelope sequence ...... ng of potent antiviral therapy
@en
P2093
A S Perelson
C C Ignacio
D D Richman
D J Looney
D V Havlir
H F Günthard
P2860
P304
P577
1999-11-01T00:00:00Z